Stockreport

Zymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting Platform

Zymeworks Inc.  (ZYME) 
Last zymeworks inc. earnings: 3/2 04:15 pm Check Earnings Report
US:NYSE Investor Relations: ir.zymeworks.com/overview
PDF Six poster presentations showcase Zymeworks’ next-generation ADC programs, including multiple first-in-class pan-RAS inhibitor ADCs Data highlight efficacy, tumor-select [Read more]